Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: A case-control study in Spain

Drug Safety

Volumn 31, Issue 6, 2008, Pages 537-543

  Rodríguez Pinilla, Elvira ^a,b   Mejías, Consuelo ^a   Prieto Merino, David ^c   Fernández, Paloma ^a   Martínez Frías, Maía L ^a,b,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Congenital disorders, drug induced; Genitourinary disorders, drug induced; Hypospadias, drug induced; Pregnancy first trimester; Valproic acid, adverse reactions

Indexed keywords

4 AMINOBUTYRIC ACID; GONADORELIN; GONADOTROPIN; VALPROIC ACID;

ARTICLE; CALCULATION; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG EXPOSURE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPOSPADIAS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEWBORN; PRENATAL EXPOSURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SPAIN;

ANTICONVULSANTS; CASE-CONTROL STUDIES; EPILEPSY; FEMALE; HUMANS; HYPOSPADIAS; INFANT, NEWBORN; LOGISTIC MODELS; MALE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRODUCT SURVEILLANCE, POSTMARKETING; RISK; SPAIN; VALPROIC ACID;

EID: 43749116421     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831060-00008     Document Type: Article

References (24)

1. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; 2: 937
2. Bjerkedal TA, Czeizel A, Goujard J, et al. Valproic acid and spina bifida [letter]. Lancet 1982; 2: 1096
3. Martínez-Frías ML, Rodríguez-Pinilla E, Salvador J. Valproate and spina bifida [letter]. Lancet 1989; 1: 611
4. Prieto L, Martínez-Frías ML. Case-control studies using only malformed infants: are we interpreting the results correctly? Teratology 1999; 60: 1-2
5. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473-81
6. Jager-Roman E, Deichi A, Jacob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997-1004
7. Lammer EJ, Sever LE, Oakley Jr GP. Teratogen update: valproic acid. Teratology 1987; 35: 465-73
8. Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171-85
9. Martínez-Frías ML. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 1990; 37: 277-82
10. Rodríguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000; 90: 376-81
11. Bertollini R, Kallen B, Mastroiacovo P, et al. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3: 164-71
12. Winter RM, Donnai D, Burn J, et al. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987; 24: 692-5
13. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42: 111-8
14. Bradaï R, Robert E. Diagnostic anténatal échographique chez la mère épileptique sous acide valproice. Etude rétrospective ou 161 cas de Registre France/Centre-Est de malformations congénitales. J Gynecol Obstet Biol Reprod 1998; 27: 413-9
15. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valpoate during pregnancy. Neurology 2005; 64: 961-965
16. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure [MADRE]. Epilepsia 2000; 41: 1436-43
17. The Centre of the ICBDSR. International Clearinghouse for Birth Defects Surveillance and Research (ICBDRS): annual report [online]. 2005; Rome. ISSN 0743-5703 Available from URL: http://www.icbdsr.org [2008 May 5]
18. Bermejo E, Cuevas L, Mendioroz J, et al. Anomalías congénitas en España: vigilancia epidemiológica en el último cuarto de siglo [1980-2004]. Boletín del ECEMC: Revista de Dismorfología y Epidemiología 2005; V (4): 62-85 [online]. Available from URL: http://bvs.isciii.es/mono/pdf/CIAC_04.pdf [Accessed 2008 May 5]
19. Prieto L, Martinez-Frias ML. Case-control studies using only malformed infants who were prenatally exposed to drugs: what do the results mean? Teratology 2000; 62 (1): 5-9
20. Martínez-Frías ML. Postmarketing analysis of medicines: methodology and value of the Spanish case-control study and surveillance system in preventing birth defects. Drug Safety 2007; 30 (4): 307-16
21. Martínez-Frías ML. Interviewer bias and maternal bias. Teratology 1993; 47: 531-2
22. Källén B. Valproic acid is known to cause hypospadias in man but not reduce anogenital distance or causes hypospadias in rats. Basic Clin Pharmacol Toxicol 2004; 94 (1): 51-4
23. Licht P, Harbarth P, Merz WE. Evidence for modulation of human chorionic gonadotropin [hCG] subunit messenger ribonucleic acid levels and hCG secretion by γ-aminobutyric acid in human first trimester placenta in vitro. Endocrinology 1992; 130: 490-6
24. Bhasin S, Heber D, Steiner BS, et al. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III: effects of long term combined treatment with GnRH agonist and androgen. J Clin Endocrinol Metab 1985; 60 (5): 998-1003